W
WAVEMAN · COMPANY
GENB · Generate Biomedicines, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

GENB

Generate Biomedicines, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0002100782
FORM 144 · 2☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
68
13F, latest reported quarter
REVENUE GROWTH
-37.7%
XBRL, annual
NET MARGIN
-1065.2%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
68 funds added or opened last quarter
more than 53% of Pharma & Biotech
REVENUE
-37.7% year over year (latest quarter)
below 79% of Pharma & Biotech
MARGIN
-1065.2% net margin (latest quarter)
below 89% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
5.7% of shares outstanding short · 15.2 days to cover · settled 2026-07-31
more than 59% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
68 funds added or opened positions in the latest 13F quarter, of 88 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +29.2%
+29.2%12M
-11%+13%+37%+61%2026-022026-032026-042026-052026-062026-072026-08 2026-03-02 · Nutritional Health LTP Fund General Partner LLC bought $25.0M2026-03-02 · Flagship Pioneering Fund VI, L.P. bought $25.0M2026-03-04 · Nally Michael bought $240.0K2026-03-02 · Mendillo Jane L bought $24.0K2026-03-02 · Silvers Jason bought $16.0K2026-03-02 · Silvers Jason bought $8.0K2026-03-02 · Grous Beth bought $4.8K2026-09-02 · ARNOLD FRANCES filed to sell $520.6K2026-09-01 · ARNOLD FRANCES filed to sell $16.0K
INSIDER BUYFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows 68 funds added last quarter, $536.6K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Generate Biomedicines, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Nally Michael
Chief Executive Officer
BUY
2026-03-04
20,000.0
$240.0K
Grous Beth
Chief People Officer
BUY
2026-03-02
300.0
$4.8K
Silvers Jason
President & CFO
BUY
2026-03-02
1,000.0
$16.0K
Silvers Jason
President & CFO
BUY
2026-03-02
500.0
$8.0K
Nutritional Health LTP Fund General Partner LLC
Director
BUY
2026-03-02
1,562,500.0
$25.0M
7 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 2 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Flagship Pioneering, LLC
62,673,117.0 sh
$1.1B
FMR LLC
5,221,599.0 sh
$88.1M
Capital World Investors
4,215,632.0 sh
$71.1M
BRAIDWELL LP
3,283,844.0 sh
$55.4M
NORGES BANK
2,094,616.0 sh
$35.3M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
ARNOLD FRANCES
FILED 2026-09-02
$520.6K
ARNOLD FRANCES
FILED 2026-09-01
$16.0K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
JPMorgan Small Cap Value Fund
$6.2M POSITION · AS OF 2026-03-31
0.5%
JPMorgan U.S. Small Company Fund
$4.9M POSITION · AS OF 2026-03-31
0.5%
LVIP JPMorgan Small Cap Core Fund
$1.1M POSITION · AS OF 2026-03-31
0.5%
JPMorgan Small Cap Value Portfolio
$1.6M POSITION · AS OF 2026-03-31
0.5%
ARK Genomic Revolution ETF
$6.4M POSITION · AS OF 2026-04-30
0.5%
U.S. Small and Mid Cap Equity Fund
$496.4K POSITION · AS OF 2026-03-31
0.5%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 6 registered trials, 5 still enrolling or running — a status change here is dated weeks before the press release
4
Phase 1
3 ACTIVE
2
Phase 3
2 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →